Under this program, District Master Training on the Introduction of DTG for HIV Infection Treatment is provided, supported by the Knowledge Hub. The initiative offers training materials, guidelines, and videos, accessible through the Knowledge Hub platform. Participants can register through SkillSMA

0 views • 8 slides

Explore the evolution of garment printing businesses like PoPATL and AnaJet, the impact of DTG technology, marketing strategies, and operational efficiencies. Learn about key players like Karl Tipre and PoPATL founders Brian Wynder and Charlie Bunkley.

0 views • 42 slides

Dolutegravir (DTG) treatment has shown associations with weight gain and clinical obesity, particularly in black individuals and women. In contrast, tenofovir disoproxil fumarate (TDF) is linked to lower body weight compared to other treatments. Trials like ADVANCE and NAMSAL have provided insights

0 views • 31 slides

Study investigating the efficacy of dolutegravir (DTG) monotherapy in early HIV-1 infection showed non-inferiority compared to standard combination antiretroviral therapy (cART). The EARLY-SIMPLIFIED study involved 68 patients on DTG monotherapy and 33 on cART, with both groups achieving HIV RNA sup

0 views • 6 slides

The ASPIRE study evaluated the efficacy of switching to DTG + 3TC in HIV patients with stable triple ART regimens. The primary endpoint was treatment failure proportion at W24, with non-inferiority demonstrated at W48. Virologic outcomes, adverse events, and patient dispositions were reported, with

0 views • 4 slides